TP53 and endometrial carcinoma: Soong et al. showed that the rate of overexpression of p53 in the nucleus was 27% and that in the cytoplasm was 54% in 122 endometrial carcinomas, respectively, whereas TP53 mutation was detected in only 13% [63].